Aktienanalyse zu CareDx, Inc. (CDNA)CDNACareDx, Inc.

CareDx, Inc. is a precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the Company is focused on improving patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; digital health technologies; and patient solutions that support care before and after transplant. The Company also provides genomic-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

CareDx Inc is a good buy right now due to its strong financial performance and positive market sentiment. The current price is $69.21, and the stock has shown a remarkable year-to-date change of +261.60%. Additionally, the gross margin has improved to 73.50% in Q2 2026, indicating effective cost management and profitability. The main risk is the forward P/E ratio of 156.25, suggesting that the stock may be overvalued based on future earnings expectations.

3 analysts cover CDNA: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 18.00.